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Four imidazo-phenanthroline (IP) based ligands and its corresponding copper polypyridyl complexes have been prepared 
[Cu(L1-L4)2]
2+ and characterized by various physicochemical techniques. Herein we are reporting the CTDNA (calf-
thymus DNA) binding & anti-cancer affinity of ligands (L1-L4) as well as complexes (C1C4). The DNA binding affinity 
of synthesized C1-C4 has been carried out by using spectroscopic techniques like UV/visible, emission, molecular modeling 
and viscosity techniques. The obtained results are clearly indicating that all C1-C4 complexes bind to DNA via intercalative 
mode and they possess a significant cytotoxic effect toward selected cancer cell lines (MDA-MB-231, B16-F10, DU-145 
and CHO-K1). 
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Many transition metal complexes well-known to 
interact with DNA have been the subject of extensive 
research in the development of new drugs in modern 
medicine.1-2 In medicinal bio-inorganic chemistry, 
cisplatin is one of the most effective and leading 
chemotherapeutic drugs against cancer, which had a 
metal coordination compound with non-organic 
units.3-7 It is not successful against numerous normal 
types of cancer growth, medicine resistance is normal 
and an unpardonable scope of symptoms, which can 
contain hair loss, damage of nerve, nausea, etc. To 
conquer these limitations, a few organic ligand-
dependent metal-based drugs have been synthesized 
and tried against various cancer cell lines. These 
complexes have a tendency to cause fewer & showing 
less side effects when compared to existing platinum-
based drugs. De Sousa et al. have reported that 
cis-Ru(II) complex exhibits significant DNA-binding, 
antibacterial and pharmacological potential agents7.  
Li et al. have executed ruthenium complexes as 
potential drugs for eukaryotic cells and intracellular 
accumulation in eukaryotic and bacterial cells8.  
Liu et al. have reported that the cis-Ru(II) complexes 
were showing significant toxic effects on eukaryotic 
cells9. Lin et al. have reported that ruthenium 
complexes are new applications for clinical antitumor 
drugs to treat tumors synergistically10. Currently, 
copper(II) complexes seem to be the best alternatives 
to platinum-containing anti-cancer drugs (ex: cisplatin) 
and ruthenium-containing anti-cancer drugs 
(ex: NAMI-A). Because copper is a fundamental trace 
mineral present on the whole body tissues and blood 
cells. It additionally helps to keep healthy the immune 
system, blood vessels and nerves system. Copper may 
also useful as antioxidant, reducing free radicals 
which can damage DNA and cells. As per previous 
reports most of the Cu-based metal complexes act as a 
potential anticancer and pharmacological agents etc.11-16 
and both cost-wise and toxicity-wise copper is the 
best metal compared to platinum and ruthenium. To 
the continuation of our work we have designed and 
synthesized new copper complexes as anticancer 
drugs to target DNA17, here we are discussing four 
copper(II) complexes as anticancer agents and binds 
to DNA via intercalative mode (Scheme 1). 
Materials and Methods 
All solvents and chemicals/reagents were acquired 
monetarily and utilized moving along without any 
more decontamination except if generally noted. 




Cu(ClO4)2·6H2O and CT-DNA and 1, 10-
phenanthroline monohydrate (C12H8N2. H2O) were 
brought from Sigma-Aldrich/Merck.  
 
Analytical measurements 
Perkin Elmer UV-visible spectrophotometer 
lambda-750 model was used for recording absorption 
spectra, Bruker 400 MHz model was used for 1H 
NMR spectra with DMSO (d6) as the solvent & 
internal standard Si(CH3)4 (tetramethylsilane) at room 
temperature. The electronic absorption spectra of 
complexes (C1-C4) were recorded both with and 
without DNA variable concentration in buffer 
solution and for complete soluble need to add a drop 
of DMSO. The buffer solution composition is 10 mM 
Tris HCl and 50 mM NaCl in buffer (pH 7.1). The 
absorption titration test finished by keeping up at a 
consistent concentration of complexes (C1-C2) 
(2.0×10-4 M) and with expanding the concentration of 
DNA over the range (0–6.0×10-4 M). The blended 
complex–DNA arrangement was permitted to 
equilibrate for 10 min at room temperature.  
 
Preparation of stock solution and in vitro cell culture 
experiments 
The required quantity of respective ligands (L1-
L4) and complexes (C1-C4) were weighed and 
dissolved in DMSO (molecular biology grade) to 
prepare a stock solution of 10 mM concentration. 
Each time we used fresh stock solutions  
for all studies. 
The cytotoxic studies of in vitro for synthesized 
C1-C2 were assessed using standard MTT (3-(4, 5-
Dimethylthiazole-2-yl)-2, 5-Diphenyltetraazolium 
bromide) analysis. Selected cells ((MDA-MB-231, 
B16-F10, DU-145 and CHO-K1) were placed in  
96-well microassay culture plates (8x103 per well) in 
200 µL in a 5% CO2 incubator were grown 12 h. 
(overnight) at 37 °C. Control wells were organized 
by addition of culture medium (200 µL). 
Doxorubicin and mitomycin & DMSO used as a +ve 
as well as vehicle controls. The absorbance was 
examined at 620 nm by using a 96-well plate reader. 
The standard solutions of the synthesized C1-C2 
were prepared in DMSO solvent, the % of DMSO 
solvent was kept in the range of 0.1–2 % because 
until 2% of DMSO found to be nontoxic to the cells. 
Results were collected for 3-repeats each to get the 
mean qualities. The ic50 values were dictated by 
plotting the % feasibility vs concentration on a 
logarithmic diagram and perusing the concentration 
at which 50% of cells remained reasonable with 




Scheme 1 — Structures of Imidazo-phenanthroline (IP) based ligands (L1-L4) and synthesized Cu(II) complexes (C1-C4) 
 





Synthesis and characterization: 1,10-
phenanthroline-5, 6-dione was synthesised as per 
literature18 IP ligands like: AIP, Tfm-PIP, IP and 
Dn-PIP, were synthesized by mixing of 1,10-phen-
5,6-dione with respective selected aldehydes as per 
the previous literature.20-22 The copper(II)polypyridyl 
complexes were synthesized readily by reacting 
copper perchlorate with the appropriate ligands; the 
complexes (C1 to C4) formed as the corresponding 
salts. A detailed procedure for the synthesis and 
characterization of ligands, as well as complexes, has 
given below. 
Preparation of 2-(anthracen-9-yl)-1H-imidazo[4,5-
f][1,10]phenanthroline (AIP): The reaction taken 
place with the mixture contains 0.53g (or) 2.50 mmol 
of 1,10, phenanthroline 5,6-dione19 with anthracene-9-
carbaldehyde (0.62 g, 3.02 mmol), add 15 mL of 
glacial acetic acid and then add 3.88 g (or)  
50.00 mmol ammonium acetate the mixture was 
refluxed for three hours18-22 and allow to cool upto 
room temperature than add water for dilution. Then 
add liquor ammonia slowly until to get yellow PPT 
then filtered, washed with water for several times then 
dray it for analysis. The product was gained about 
79% yield; 1H-NMR (DMSO-d6, 300 MHz, δ ppm): 
9.12-8.80 (m, 4H), 8.12-8.16 (m, 2H), 8.08 (s, 1H), 
7.88-7.77 (m, 4H), 7.61-7.49 (m, 4H). ESI-MS: m/z = 
397 (M+H) peak observed (Supplementary Data). 
Preparation of 2-(4-(trifluoromethoxy)phenyl)-1H-
imidazo[4,5-f][1,10]phenanthroline (Tfm-PIP): The 
reaction taken place with the mixture contains 0.53g 
(or) 2.50mmol of 1,10, phenanthroline 5,6, dione19 
with 4-(trifluoromethoxy) benzaldehyde (0.57 g,  
3.02 mmol), add 15 mL of glacial acetic acid and then 
add 3.88 g (or) 50.00 mmol ammonium acetate the 
mixture were refluxed for three hours18-22 and allow to 
cool upto room temperature than add water for 
dilution. Then add liquor ammonia slowly until to get 
yellow PPT then filtered, washed with water for 
several times then dray it for analysis. The product 
was gained about 76% yield; 1H-NMR (DMSO-d6, 
300 MHz, δ ppm): 9.05 (d, J = 4.1 Hz, 2H), 8.92 (d, J 
= 8.0 Hz, 2H), 8.38 (d, J = 8.6 Hz, 2H), 7.81-7.78 (m, 
2H), 7.58 (d, J = 8.4 Hz, 2H); ESI-MS: m/z = 381 
(M+H) peak observed (Supplementary Data). 
Preparation of 1H-imidazo[4,5-f]-[1,10] 
phenanthroline (IP): The reaction taken place  
with the mixture contains 0.53 g (or) 2.50 mmol of 
1,10, phenanthroline 5,6, dione19 with formaldehyde 
(0.09 g, 3.02 mmol), add 15 mL of glacial acetic acid 
and then add 3.88 g (or) 50.00 mmol ammonium 
acetate the mixture were refluxed for three hours18-22 
and allow to cool upto room temperature than add 
water for dilution. Then add liquor ammonia slowly 
until to get yellow PPT then filtered, washed with 
water for several times then dray it for analysis. The 
product was gained about 72% yield; 1H-NMR 
(DMSO-d6, 300 MHz, δ ppm): 8.19-8.17 (m, 2H), 
7.98-7.96 (m, 2H), 7.61 (s, 1H), 6.99-6.95 (m, 2H). 
ESI-MS: m/z = 221 (M+H) peak observed 
(Supplementary Data). 
Preparation of 2-(2,4-dinitrophenyl)-1H-
imidazo[4,5-f][1,10]phenanthroline (Dn-PIP): The 
reaction taken place with the mixture contains 0.53 g 
(or) 2.50 mmol of 1,10, phenanthroline 5,6, dione19 
with 2,4-dinitrobenzaldehyde (0.59 g, 3.02 mmol), 
add 15 mL of glacial acetic acid and then add 3.88 g 
(or) 50.00 mmol ammonium acetate the mixture were 
refluxed for three hours18-22 and allow to cool upto 
room temperature than add water for dilution. Then 
add liquor ammonia slowly until to get yellow 
precipitate then filtered, washed with water for 
several times then dray it for analysis. The product 
was gained about 72% yield; 1H-NMR (DMSO-d6, 
300 MHz, δ ppm): 8.19-8.17 (m, 2H), 7.98-7.96 (m, 
2H), 7.61 (s, 1H), 6.99-6.95 (m, 2H). ESI-MS: m/z = 
387 (M+H) peak observed (Supplementary Data). 
 
Synthesis of Copper (II) complexes 
Complexes (C1-C4): It was synthesized by the 
following reported procedure.23 The mixture of 
commercially available Cu(ClO4)2. 6H2O (0.1 mmol) 
of with 0.2 mmol of AIP ligand in 15 ml of solvent 
(methanol) under stirring about 2 h at room 
temperature. The precipitate which was formed was 
separated from mixture, washed with methanol (cold 
condition) then dried under vacuum; FTIR (KBr): 
3445, 1607, 1543, 1407, 1358, 1083, 731, 621 cm-1; 
ESI-MS: m/z = 856 (M)+ peak observed 
(Supplementary Data). Calculated CHN analysis for 
complex 1 are: C 61.25, H 3.08, N 10.58 and obtained 
are C 60.1, H 2.8, N 9. 8. The synthesis of [Cu(Tfm-
PIP)2] complex is similar to above procedure and 
analytical data for characterisation of complex is FT-IR 
(KBr): 3079, 1611, 1522, 1482, 1458, 1260, 1211, 
1098, 810, 727, 621 cm-1; ESI-MS: m/z = 823 (M)+ 
peak observed. Calculated CHN analysis for complex 2 
are: C 46.79, H 2.20, N 10.9 and obtained are C 44.9, 
H 1.9, N 9.2. The synthesis of [Cu(IP)2] complex is 
similar to above procedure and analytical data for 
characterisation of complex is FT-IR (KBr): 3123, 




1610, 1538, 1417, 1358, 1112, 1083, 813, 730, 625 cm-1; 
ESI-MS: m/z = 503 (M)+ peak observed (SI). 
Calculated CHN analysis for complex 3 are: C 44.2, H 
2.34, N 15.9 and obtained C 42.9, H 2.1, N 12. 2. The 
synthesis of [Cu(Dn-PIP)2] complex is similar to above 
procedure and analytical data for characterisation of 
complex is FT-IR (KBr): 3378, 3073, 2924, 1603, 
1527, 1349, 1114, 1079, 810, 735, 625 cm-1; ESI-MS: 
m/z = 835 (M)+ peak observed (Supplementary Data). 
Calculated CHN analysis for complex 4 are: C 43.9, H 
1.98, N 16.18 and obtained C 42.7, H 2.0, N 15. 2. 
 
Results and Discussion  
 
DNA-Binding characteristics of complexes  
 
Analysis with absorption spectroscopy technique  
The drug molecule interaction with CT-DNA is 
mainly via two modes that were intercalative mode 
and non-intercalative mode, in detail (i) major/minor 
groove binding (ii) intercalative binding in the middle 
of the base sets of DNA and (iii) electrostatic binding 
with the negatively-charged nucleic sugar.24-25 The 
absorption spectra of the synthesized C1-C4 were 
analyzed within the absorption range between 200 to 
800 nm in tris buffer at required concentrations of 
complexes (C1-C4) as shown in Fig. 1. The 
absorbance of a solute depends linearly on  
its concentration and therefore, absorption 
spectroscopy is preferably very well-suited for 
quantitative measurements. Absorption titrations were 
accomplished by maintaining a consistent 
concentration of C1-C4 while increasing the 
concentration of the CT-DNA (0–200 µM) until the 
saturation point was recognized. The reaction solution 
needs to blend carefully and be permitted to stand 
about 3 to 5 minutes before each run of the scan. The 
characteristic peaks of π−π* ligand transitions 
obtained in expected UV-region and MLCT (metal-
ligand charge transfer) peaks at the visible region. At 
the saturation point, there is no change in intensity by 
the addition of DNA. In the quantitative analysis, we 
were plotting that the 0/ vs [DNA], 0 &  are the 
hypochromism intensities of C1-C4 without and with 
DNA. The given binding constants (Kb) were 
determined by using the following well-known 





At a given particular DNA concentration εa is the 
extinction coefficient obtained for MLCT, the 
extinction coefficient of DNA is εf and the extinction 
coefficient of Cu(II) complex is εb for completely 
bound to CT-DNA. In graph plots of [DNA] versus 
[DNA]/(εb−εf), the Kb is shown by the ratio of the 
slope to intercept. The non-linear least-square 
investigation was performed by using Origin lab 
software. The obtained Kb values for selected copper 
complexes are 3.68104, 2.58104, 3.05103 and 
1.38104 M−1 for C1, C2, C3 and C4, respectively. 
 
Fluorescence Spectra  
In this spectroscopy, we can measure both 
excitation and emission spectra of the selected 
sample. The emission intensity is directly proportional 
to the concentration of the sample. Usually, metal 
complexes bind to DNA they show changes in 
fluorescence spectra. In this experiment, we took a 
fixed concentration synthesized complex in solution 
(10 μM) and to this adding DNA with varying 




Fig. 1 — UV-visible absorption titration spectra of complex C1
(a) and C2 (b), [that of C3 and C4 are given in Supplementary 
Data] in the absence (top) and presence (lower) of DNA. The
arrow shows that by adding the DNA solution (increasing DNA
conc. in the reaction mixture) the absorbance changes 
 




fluorescence spectrum. The luminescence of selected 
C1-C2 at ambient condition shows λmax at  
250−750 nm, and when it interacts with CT-DNA 
was observed with luminescence. The emission 
titration results for complex 4 (A) and complex 2 (B) 
when binding with CT-DNA are presented in Fig. 2. 
Continue supply of DNA solution, the emission 
intensities increase for these complexes, showing their 
strong DNA binding capacity (for complexes C1 and 
C3 (Supplementary Data)). 
 
Fluorescence quenching 
Quenching experiments were studied using 
benchmark quencher [Fe(CN)6]
4- for further support. 
Without complexes were efficiently quenched with a 
quencher and the combination of DNA + complex, 
showing very less quenching effect. This may 
possibly due to strong negative (–ve) charged 
ferrocyanide ion would have repelled by the negative 
charge of the DNA phosphate backbone and hindered 
the quenching ability of the bound complexes. This 
can be further illustrated by the fact that interacted 
cations of the copper(II) complexes (Cu(II)) are 
protected from the negative charged bound quencher 
by the same charged DNA phosphate groups and 
hindered quenching of bound complex.27-28 The 
binding affinity can be determined by the slope of the 
curve. The quenching constant Ksv determined with 
the help of previous reports29 (Eqn (2)). 
 
I0/I = 1+Ksv[Q]    …(2) 
 
where I0 and I are the fluorescence intensities in the 
absence and presence of ferrocyanide (quencher), 
concentration of the quencher is Q and linear Stern-
Volmer is Ksv. In this plot of I0/I vs [Q], Ksv is the 
slope. The ferrocyanide quenching plot for complex 1 
in the absence, presence and excess of DNA is  
shown in Fig. 3.  
 
Viscosity measurements  
Viscosity of a liquid is the resistance of the liquid 
to flow. Simply a liquid having less viscosity may 
flows faster due to the minor friction between the 
molecular faces when it is in motion and more 
viscosity means the molecular faces have more 
internal friction. In this particular analysis, the 
viscosity technique was utilized for further 
confirmation of mode of interaction between 
 
 
Fig. 2 — Fluorescence emission intensity spectra of complex 4 (a)
and complex 2 (b) in tris buffer with addition of DNA solution,
where [C1-C4] = 10 μM, [DNA]/ C1-C4 = 0, 5, and 10. The
arrows show that with increasing concentration of DNA the




Fig. 3 — Emission quenching of complex C1 with K4[Fe(CN)6] in 
the absence (a) and presence (b) [Cu] =20 mM and excess of
DNA (c) 




synthesized copper(II) complexes (C1-C4) and DNA. 
As per Satyanarayana et al., if DNA length increases 
when drug accomodated in between the base pairs at 
intercalation sites, it will increase the viscosity of 
complex + DNA solution and this is a strong property 
of intercalation binding mode of complexes. On the 
other hand, complexes that can bind through groove 
generally cause less or no variation in viscosity 
values.30a-b From results obtained on relative viscosity 
values of DNA + complexes enhances with increasing 
the concentration of the complexes revealed that the 
intercalation mode of binding with DNA (Fig. 4). It is 
due to more planarity of ligands with corresponding 
complexes (C1, C2 & C4) and are showing more 
intercalative values than C3 which is having less 
planar aromatic ligand (PIP). This is in good 
agreement with the obtained results from UV-
visible/fluorescence emission intensity spectra.30a-b  
 
Molecular docking studies 
Molecular Modelling Technique (MMT) can be a 
very useful process in new drug discovery. It mainly 
includes theoretical analysis and computational 
methods. The docking is an analysis in MMT, which 
gives the coordination of one to other molecules when 
binding each other and form a stable complex.31 Based 
on the in vitro results, we have performed the 
molecular docking studies, in which we selected a 
topoisomerase II-A bound with G-segment of DNA 
(PDB ID: 2RGR) from protein data bank (PDB), as the 
prepared complexes show evidence in vitro results that 
are more tend to bind the DNA. DNA-topoisomerases 
enzymes are a major target for cancer drugs and show a 
very important role in the relaxation of DNA. In the 
DNA replication process, relaxation of DNA is the 
most important step. DNA-topoisomerase reduces 
binding to transient enzyme-DNA complexation and 
results in inhibition of DNA replication.  
Protein receptor is optimized by removing all the 
heteroatoms, water molecules using discovery studio 
4.5 clients. Polar hydrogen atoms, Kolman charges 
were added in auto dock. The complex structures 
were drawn and cleaned in chemsketch added 
gasteiger charges to it in auto dock and optimized for 
docking in autodock vina. A grid was created in 
protein for synthesized ligands binding with 
optimized X, Y and Z coordinates, this program was 
kept running in order brief for a best fitting model in 
auto dock vina. The complexes C1-C4 showing 
binding affinity in between 22 to 25 kcal/mol and the 
results are supporting that synthesized complexes are 
strongly binding to DNA through intercalative mode, 
which can correlate with viscosity results. (Fig. 5). 
The scores fitness values in the range 22 to 25 
kcal/mol represent intercalation mechanism in 
between DNA and complexes due to some van der 
Waals forces and hydrogen bonds. Correlation 
between spectroscopic investigation and docking 




Fig. 4 — Upon addition of complexes (C1-C4) the effect of
viscosity of DNA increases at room temperature and models for




Fig. 5 — Docking models of complex C1 and complex C2 




interaction in between selected complexes (C1-C2) & 
DNA, which are important for the design of new 
drugs that are more useful for understanding the 
mechanism of drugs at the molecular level. 
 
Cytotoxicity activity 
As per the reports on the cytotoxicity of copper 
complexes17, we have screened the synthesized 
ligands (L1-L4) as well as prepared complexes  
(C1-4C4) for their anticancer activity. The activity of 
ligands and complexes were tested against five 
different cell lines along with doxorubicin and 
mitomycin as positive control and all of them showed 
reasonable to decent anticancer effects. The collected 
results are in Table 1 for 72 h, and in Table 2 for 27 h 
duration. The complexes whose IC50 values are 
showing to be lower and closer to the reference drugs 
like doxorubicin & mitomycin and can be considered 
to have decent anticancer potential. By comparing the 
IC50 values of ligands and complexes, we can clearly 
understand that the complexes are more active than 




2+ complexes were 
prepared with imidazo-phenanthroline (IP) based 
ligands which can act as an efficient DNA-binders 
and characterized by various physicochemical 
techniques. Based absorption/emission spectrum 
titrations experiment results that complexes (C1-C4) 
showing hypochromic/hyperchromic effects by 
addition of CT-DNA indicating that strong binding 
with Kb values  104 and quenching studies further 
supports that strong binding of the complexes to 
DNA. Photoactivated cleavage experiment clearly 
indicates the ability to cleave the circular DNA. 
Viscosity measurements and molecular modeling 
technique are clearly indicating the strong binding of 
these complexes with DNA through intercalitive 
mode. The synthesized complexes possess a 
significant cytotoxic effect toward several cancer cell 
lines MDA-MB-231, B16-F10, DU-145 and CHO-
K1. The obtained results are opening a new venture to 
design new drugs for cancer lines. 
 
Supplementary Data 
Supplementary Data associated with this article are 
available in the electronic form at 
http://nopr.niscair.res.in/jinfo/ijca/IJCA_60A(01)37-
44_SupplData.pdf. The supplementary data contains 
the information relating to characterization of the 
 
Table 1 — The IC50 value of lignads (L1-L2) as well as copper complexes (C1-C4) in comparison with recently reported copper 
complexes (treatment duration: 24 h) 
S. No. Test compound IC50 values (μM) 
MDA-MB-231 SKOV3 MCF7 DU145 HepG2  
1 Complex-1 7.2± 0.72 8.6± 0.66 8.2± 0.41 5.2± 0.37 8.8± 0.37 
2 Complex-2 7.9± 0.57 6.9± 0.46 7.6± 0.17 4.9± 0.24 7.7± 0.47 
3 Complex-3 105.6± 0.43 9.8± 0.52 20.6± 0.26 7.7± 0.32 13.2± 0.38 
4 Complex-4 8.1± 0.56 10.7± 0.45 7.9± 0.74 6.3± 0.58 8.6± 0.47 
5 Ligand-1 19.9± 0.23 15.1± 0.12 14.8± 0.34 10.7± 0.72 19.5± 0.37 
6 Ligand-2 12.7± 0.32 6.6± 0.21 8.7± 0.45 5.5± 0.26 13.4± 0.67 
7 Ligand-3 74.3± 0.44 67.6± 0.32 16.4± 0.21 32.5± 058 10.9± 0.76 
8 Ligand-4 20.8± 0.66 NA 17.4± 0.12 23.7± 0.77 88.3± 0.56 
Standard Drug- Doxorubicin 0.7 ± 0.12 0.8 ± 0.14 0.7 ± 0.15 0.6 ± 0.11 0.8 ± 0.12 
 
Table 2 — IC50 value of lignads (L1-L2) as well as copper complexes (C1-C4) in comparison with recently reported copper complexes 
(treatment duration: 48 h) 
S. No. Test compound IC50 values (μM) 
MDA-MB-231 SKOV3 B16-F10 DU145 CHO 
1 Complex-1 2.4 ± 0.66 7.3 ± 0.81 7.5 ± 0.0.74 4.5 ± 0.64 10.7 ± 0.60 
2 Complex-2 1.6 ± 0.51 6.3 ± 0.60 8.2 ± 0.65 3.2 ± 0.53 4.6 ± 0.55 
3 Complex-3 2.7 ± 0.37 7.7 ± 0.57 7.8 ± 0.84 4.4 ± 0.67 4.8 ± 0.63 
4 Complex-4 2.4 ± 0.43 7.6 ± 0.62 8.5 ± 0.72 4.9 ± 0.70 1.5 ±0.37 
5 Ligand-1 4.9 ± 0.58 10.3 ± 0.67 10.4 ±0.87 6.8 ± 0.77 6.4 ± 0.51 
6 Ligand-2 2.1 ± 0.40 6.1 ± 0.73 11.9 ± 0.54 5.1 ± 0.66 2.0 ± 0.49 
7 Ligand-3 8.1 ± 0.64 40.3 ± 0.52 10.9 ± 0.49 9.3 ± 0.74 4.8 ± 0.74 
8 Ligand-4 5.8 ± 0.71 182.5 ± 1.4 15.0 ± 0.57 6.0 ± 0.58 2.7 ± 0.58 
Standard Drug- Doxorubicin 0.7 ± 0.22 0.8 ± 0.21 2.1 ± 0.24 0.7 ± 0.20 - 
Mitomycin C - - - - 11.3 ± 0.33 
 




synthesized ligands and copper complexes and also 
the list of abbreviations used in this article. Fig. S1 
and S2 are related to the absorption and emission 
spectra, respectively, of C1-C4. Fig. S3 to S6 related 
NMR spectrum of ligands and copper complexes  
(C1-C4). Fig. S7-12 related is related to the mass 
spectrum of ligands and complexes (C1-C2). Fig. S13 
is related to photoactivated cleavage of pBR 322 
DNA by copper complexes. 
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